Loading
A phase 1/2 trial of JK08, Pembrolizumab in metastatic cancer and melanoma, run by Salubris Biotherapeutics Inc, active and no longer recruiting.
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer is a phase 1/2 interventional study registered as NCT05620134 by Salubris Biotherapeutics Inc, with 263 participants planned, started 2022-10-17 and due to reach its primary completion in 2025-10-17. Interventions recorded: JK08, Pembrolizumab, Lenvatinib Pill. Conditions listed: Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer. No results are recorded here; the registry entry is the source.